ESMO 2023: Recommendations From Dr. Reshma Mahtani for Breast Cancer
Friday, October 20, 2023
14:00–15:40 CEST; Proffered Paper Session
Breast Cancer, Early Stage
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. N Harbeck
LBA21 KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. F Cardoso
Saturday, October 21, 2023
10:15–11:35 CEST; Proffered Paper Session
Breast Cancer, Metastatic
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study. S Modi
Saturday, October 21, 2023
Posters
Breast Cancer, Metastatic
389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). J Cortés
Sunday, October 22, 2023
8:30–9:55 CEST; Mini Oral Session
Breast Cancer, Metastatic
382MO - Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. NU Lin
Monday, October 23, 2023
16:30–18:00 CEST; Mini Oral Session
Breast Cancer, Early Stage
LBA23 Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). A Bardia
Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 3
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial. A Bardia
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: